Table 3 Serum immunologic profile and clinical symptoms in study population at time of diagnosis
From: Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Variable | CPFE | IPF |
|---|---|---|
|  | Number (n) – frequency (%) | Number (n) – frequency (%) |
Total number | 40 | 60 |
ANA | 17 (42.5)* | 16 (26.7) |
Anti-ds DNA | 0 | 2 (3.3) |
Anti-Ro (SSa) | 0 | 0 |
Anti-La (SSb) | 0 | 0 |
p-ANCA (MPO) | 7 (17.5)* | 0 |
c-ANCA | 0 | 0 |
RF | 3 (7.5) | 6 (10) |
Anti-CCPs | 2 (5) | 4 (6.6) |
Anti-scl 70 | 1 (2.5) | 2 (3.3) |
Renal biopsy consistent of MPA | 3 (7.5) | NA |
Arthralgia | 3 (7.5) | 6 (10) |
Morning Stiffness | 2 (5) | 6 (10) |
Raynaud’s phenomenon | 4 (10) | 2 (3.3) |
Dysphagia | 1 (3) | 2 (3.3) |
Hemoptysis | 2 (5) | 0 |
Hematuria | 7 (17.5)* | 0 |